Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Accumulated Expenses data on file, last reported at $69.8 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $69.8 million, up 848.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.8 million (up 848.82% YoY), and the FY2025 annual result was $97.8 million, up 7.44% from the prior year.
• Accumulated Expenses retreated to $69.8 million in Q1 2026 per DNLI's latest filing, from $97.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $97.8 million in Q4 2025 and troughed at $4.8 million in Q3 2024.
• A 5-year average of $29.4 million and a median of $10.3 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses plunged 70.45% in 2024, then surged 848.82% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $66.7 million in 2022, then increased by 2.71% to $68.5 million in 2023, then surged by 32.95% to $91.1 million in 2024, then advanced by 7.44% to $97.8 million in 2025, then slipped by 28.69% to $69.8 million in 2026.
• Business Quant data shows DNLI's Accumulated Expenses at $69.8 million in Q1 2026, $97.8 million in Q4 2025, and $4.9 million in Q3 2025.